Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial.

ABSTRACT:

Objective

The objective was to evaluate the efficacy and safety of single-dose ketamine infusion in adults with sickle cell disease (SCD) who presented with acute sickle vasoocclusive crisis (VOC).

Methods

This study was a parallel-group, prospective, randomized, double-blind, pragmatic trial. Participants were randomized to receive a single dose of either ketamine or morphine, infused over 30 min. Primary outcome was mean difference in the numerical pain rating scale (NPRS) score over 2 h. NPRS was recorded every 30 min for a maximum of 180 min and secondary outcomes were cumulative dose of opioids, emergency department (ED) length of stay, hospital admission, change in vital signs, and drug-related side effects. Authors performed the analysis using intention-to-treat princ

SUBMITTER: Alshahrani MS 

PROVIDER: S-EPMC9292870 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature